MedPath

Effect of oxygen supplement during hemodialysis on serum erythropoietin and hemoglobin in end stage renal disease patient

Phase 3
Recruiting
Conditions
End&#45
stage renal disease&#44
normobaric oxygen paradox
Registration Number
TCTR20161230004
Lead Sponsor
Ratchadapiseksompotch Fund
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
8
Inclusion Criteria

1)End-stage renal disease patients who had regular hemodialysis at King Chulalongkorn memorial hospital
2)Age older than 18 years
3)Stable erythropoietin supplement at least 2 months

Exclusion Criteria

1)Gastrointestinal bleeding in 3 months
2)Chronic lung diseases

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
erythropoietin 6 weeks erythropoietin level
Secondary Outcome Measures
NameTimeMethod
anemia 6 weeks hemoglobin, reticulocyte count
© Copyright 2025. All Rights Reserved by MedPath